{"id":"flecainide-controlled-release","safety":{"commonSideEffects":[{"rate":"19–21%","effect":"Dizziness"},{"rate":"10–12%","effect":"Dyspnea"},{"rate":"6–10%","effect":"Palpitations"},{"rate":"4–6%","effect":"Chest pain"},{"rate":"5–7%","effect":"Tremor"},{"rate":"3–5%","effect":"Blurred vision"},{"rate":"1–3%","effect":"Proarrhythmic effects (new or worsened arrhythmias)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Flecainide inhibits the fast inward sodium current in cardiac tissue, which decreases the rate of depolarization and slows conduction through the atria and ventricles. This action suppresses ectopic activity and stabilizes the electrical properties of the myocardium. The controlled-release formulation provides sustained drug levels to maintain antiarrhythmic efficacy over an extended dosing interval.","oneSentence":"Flecainide is a Class IC antiarrhythmic that blocks cardiac sodium channels to slow conduction velocity and suppress abnormal electrical activity in the heart.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:46:33.732Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Paroxysmal supraventricular tachycardia (PSVT)"},{"name":"Paroxysmal atrial fibrillation"},{"name":"Ventricular arrhythmias"}]},"trialDetails":[{"nctId":"NCT07405671","phase":"PHASE4","title":"Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation","status":"NOT_YET_RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2026-09","conditions":"Atrial Fibrillation (AF), Coronary Artery Disease","enrollment":988},{"nctId":"NCT06783868","phase":"","title":"Assessing the Neurological Outcomes After Atrial Fibrillation Ablation for Rhythm Control","status":"NOT_YET_RECRUITING","sponsor":"Kansas City Heart Rhythm Research Foundation","startDate":"2025-10","conditions":"Atrial Fibrillation, Stroke","enrollment":100},{"nctId":"NCT05631730","phase":"PHASE3","title":"Effect and Safety of Flecainide and Metoprolol Versus Metoprolol Alone to Suppress Ventricular Arrhythmias in Arrhythmic Mitral Valve Prolapse","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2023-01-04","conditions":"Mitral Valve Prolapse, Ventricular Arrhythmias and Cardiac Arrest","enrollment":50},{"nctId":"NCT03437356","phase":"NA","title":"Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drugs in Persistent Atrial Fibrillation","status":"COMPLETED","sponsor":"AZ Sint-Jan AV","startDate":"2018-02-26","conditions":"Atrial Fibrillation","enrollment":210},{"nctId":"NCT00189319","phase":"PHASE4","title":"To Evaluate the Impact of Oral Flecainide on Quality of Life in Patients With Paroxysmal Atrial Fibrillation","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2003-09","conditions":"Atrial Fibrillation","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Flecainide controlled release","genericName":"Flecainide controlled release","companyName":"MEDA Pharma GmbH & Co. KG","companyId":"meda-pharma-gmbh-co-kg","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Flecainide is a Class IC antiarrhythmic that blocks cardiac sodium channels to slow conduction velocity and suppress abnormal electrical activity in the heart. Used for Paroxysmal supraventricular tachycardia (PSVT), Paroxysmal atrial fibrillation, Ventricular arrhythmias.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}